AVEO Pharmaceuticals Long Term Debt

AVEO Pharmaceuticals (AVEO) currently reports a long-term debt of $27M as of September 2022. That compares with $33M in the prior-year period — down 17.7% year over year. Use the charts on this page to explore AVEO Pharmaceuticals's long-term debt history and peer comparisons.

AVEO Pharmaceuticals's long-term debt decreased from $33M to $27M — a 17.7% year-over-year decrease (period ending September 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

AVEO Pharmaceuticals reported $27M in long-term debt as of September 2022. That compares with $33M in the prior-year period — down 17.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $27M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for AVEO Pharmaceuticals, and consider following AVEO for alerts when major investors trade the stock.

AVEO Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $27M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AVEO with unrelated industries.